BLC USA, founded in Nashville, Tennessee, is a medical R&D firm dedicated to combating the global crisis of drug-resistant bacteria. The company's core mission is to develop innovative solutions to address Antimicrobial Resistance (AMR). BLC USA collaborates with international experts and visionary companies to advance early-stage projects through clinical trials. Their market focus is on the US, where the threat of AMR, particularly gram-negative infections, is a growing concern.

Notable affiliated people include a team of scientists and professionals who work closely with international partners. While specific investors are not mentioned, the company's collaborative efforts highlight its extensive network. Key achievements include advancing clinical trials for new antibiotics to combat AMR. BLC USA's impact lies in its critical role in developing new treatment options as the world faces diminishing antibiotic efficacy.